US EditionBexion Pharmaceuticals, Inc. Announces Acceptance of Abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
- Bexion Pharmaceuticals, Inc. Announced that two abstracts on its biologic therapy were accepted at the 2025 ASCO Annual Meeting in Chicago from May 30 to June 3.
- The acceptance follows multiple Phase 1 trials in adults and children showing BXQ-350’s safety and single-agent activity against various solid tumors.
- BXQ-350 is being studied for its effects on various solid tumor types such as colorectal cancer, aggressive gliomas, and brain tumors in children, as well as for its potential to treat chemotherapy-induced peripheral neuropathy .
- The Company completed enrollment in a Phase 1b/2 study combining BXQ-350 with standard care and a proof-of-concept trial for CIPN, where the therapy shows promise.
- These developments suggest BXQ-350’s potential to address high unmet needs in solid tumors and CIPN, with upcoming data presentations expected at ASCO 2025.
Insights by Ground AI
Does this summary seem wrong?
29 Articles
29 Articles
All
Left
Center
7
Right
6
LoudounTimes.com+28 Reposted by 28 other sources
Bexion Pharmaceuticals, Inc. Announces Acceptance of Abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
COVINGTON, Ky., May 28, 2025 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced that two abstracts were accepted at the…
Coverage Details
Total News Sources29
Leaning Left0Leaning Right6Center7Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
C 54%
R 46%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
